 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 160098-96-4 |
| Molecular formula(MF) | C18H15N7O |
| Molecular Weight(MW): | 345.36 |
| Alias |
| In vitro | DMSO | 69 mg/mL (199.79 mM) |
|---|---|---|
| Water | <1 mg/mL | |
| Ethanol | <1 mg/mL | |
| In vivo |
| Description | SCH 58261 is a potent and selective A2a adenosine receptor antagonist with Ki of 2.3 nM and 2 nM for rat A2a and bovine A2a, respectively. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro |
SCH 58261 causes the inhibition of rabbit platelet aggregation and porcine coronary artery relaxation by antagonizing competitively the effects induced by CGS 21680. [1] |
||||
| In vivo | In mice with Spinal cord injury, SCH58261 (0.01 mg/kg, i.p.) reduces demyelination and levels of TNF-α, Fas-L, PAR, Bax expression and activation of JNK MAPK. Chronic SCH58261 administration improves the neurological deficit up. [2] In rats with 6-OHDA-induced Parkinson's disease, SCH58261 (2 mg/kg, i.p.) improves the 6-OHDA-induced bradykinesia and motor disturbance. [3] |